Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
E: investors.relations@vivalis.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,021.90 | 60.20 | 0.76% |
| CAC 40 | 7,290.49 | 39.48 | -0.54% |
| DAX 40 | 21,215.72 | 95.30 | -0.45% |
| Dow JONES (US) | 39,669.39 | 699.57 | -1.73% |
| FTSE 100 | 8,234.80 | 40.80 | -0.49% |
| HKSE | 21,395.14 | 338.16 | 1.61% |
| NASDAQ | 16,307.16 | 516.01 | -3.07% |
| Nikkei 225 | 34,377.60 | 457.20 | 1.35% |
| NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
| S&P 500 | 5,275.70 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
| SSE Composite Index | 3,280.34 | 4.34 | 0.13% |